| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5658974 | Gastroenterology | 2016 | 30 Pages |
Abstract
In a randomized phase 2 study of patients with HCC of BCLC stages A or B, we found Y90 radioembolization to provide significantly longer TTP than cTACE. Y90 radioembolization provides better tumor control and could reduce drop-out from transplant waitlists. ClinicalTrials.gov no. NCT00956930.
Keywords
conventional transarterial chemoembolizationcTACETTPEASLBCLCRadioembolizationHCCEuropean Association for the Study of the Liveroverall survivalcomputed tomographyTime to progressionWorld Health OrganizationLiver cancerChemoembolizationconfidence intervalhazard ratiorandomized trialHepatocellular carcinomaKaplan–MeierBarcelona Clinic Liver CancerWHOYttrium-90
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Riad Salem, Andrew C. Gordon, Samdeep Mouli, Ryan Hickey, Joseph Kallini, Ahmed Gabr, Mary F. Mulcahy, Talia Baker, Michael Abecassis, Frank H. Miller, Vahid Yaghmai, Kent Sato, Kush Desai, Bartley Thornburg, Al B. Benson, Alfred Rademaker,